Andrea R. Filippi
@AndrearicFiliAssociate Professor of Radiation Oncology at the University of Milan. Chair of Radiotherapy Department at Istituto Nazionale Tumori, Milan, Italy
Similar User
@bslotman
@Icro_Meattini
@Mat_Guc
@alongi_filippo
@PBlanchardMD
@DanTrifMD
@SBRT_CR
@CTuscanoMD
@ZilliThomas
@StAr_MCM74
@NicosiaMd
@AmarUKishan
@GiulioFrancoli1
@finn_corinne
@chelseajm28
Radiation induces over expression of both PDL1 and tigit, perhaps there is still a chance for skyscraper 03. And agree that rilvegostomig could be more powerful it’s kind of another mechanism, for both NSCLC and SCLC @Alfdoc2
I think Skyscraper will be the decider one way or another for anti-Tigit monospecifics but not sure even if negative we should exclude bispecifics eg rilvegostomig.
🔍 NSCLC insights from #ESMO2024! Prof Dr @AndrearicFili: PACIFIC-R data indicate a 19.4% pneumonitis rate in NSCLC patients treated with CRT and durvalumab. Watch now! medimix.be/onco/esmo-barc… #MediMix #LungCancer #Oncology #NSCLC
🚀 We’re back! 🚀Exciting news! The Radiotherapy & Oncology (Green Journal) is relaunching on Twitter! Follow us for the latest breakthroughs in #Radiotherapy, #Oncology, expert insights, and cutting-edge research. Stay connected with the global radiation oncology community!
My dad died just 3 months after he was diagnosed with #LungCancer. My mom died only 6 months after her diagnosis. I’ve now lived with lung cancer for 15 years—a gift made possible by advancements in research that gave me options my mom and dad never had. But we can’t stop here.…
As @jillfeldman4 says, #research is not just about science. It’s about people. About giving them a chance. Jill’s personal story is hard to fathom and illustrates why it’s so important to her that research bring every person and family a chance. #BecauseofResearch #LCAM
Si sta avvicinando la nuova edizione del corso "TUMORI POLMONARI TRA PRESENTE E FUTURO" a Genova. Sarà un'occasione di aggiornamento su stato dell'arte e prospettive nelle neoplasie polmonari. Per iscriversi: fad.accmed.org/course/info.ph… Vi aspettiamo! @ACCMEDorg @WalceOnlus2006
Join @samsonpp @AndrearicFili and me for @IASLC webinar on Case Based Controversies in Locally Advanced NSCLC 11/18/2024. iaslc.org/meetings-webin… @StephenChunMD @MDAndersonNews @DrAlexLouie @WashUMedRadOnc
Another study suggests that the kind of local therapy (surgery or RT) might not impact survival when coupled with the same systemic treatment in the same patients groups. @LungCaJournal lungcancerjournal.info/article/S0169-…
In this registry-based, real-world observational study, 1/3 of stage 2-3 NSCLC patients judged as resectable or borderline resectable at baseline received RT as local therapy. lungcancerjournal.info/article/S0169-…
Excited to share our new study @Nature Very grateful for the support of our collaborators, pharma and biotech partners and members of the Skoulidis and Heymach labs. Special thanks to star fellow @_hanielaraujo and @minhtruongdo Thankful to our patients. @MDAndersonNews
Dr. @RobertoFerrara_ delivers a brilliant summary of #NTRK #RET and #MET NSCLC. Important point on RET is trial demographics vs real world (inc histology), which impacts outcomes. Multiple targeted agents available for all of these but resistance still a challenge. #ILCS24
Attending online #ILCS24 , wonderful event , very nice interaction
Andrea R. Filippi memoinoncology.com/videos/andrea-… via @memoinOncology
Starting now! From Lausanne, Switzerland, join #ILCS24 virtually with interactive video or text questions available. Outstanding faculty for the 6th annual International Lung Cancer Summit chaired by Drs. @Alfdoc2 and @peters_solange! Register now at lungsummit.org
#ASTRO24 Terrific early morning #lungcancer session🫁‼️ @BenLok reporting on tolerability of PARPi with IMRT as consolidation in patients with ES-SCLC🙏 Important to restrict esophagitis‼️ Excellent basis for future development of PARPi in this space👍 #LCSM
after 1 long year the #ILCS24 is about to start. jjoin us tomorrow lungsummit.org Honored to co-chair it with @peters_solange and to share the stage with such great faculty @StephenVLiu @DrJNaidoo @PatelOncology @RobertoFerrara_ @BiagioRicciutMD Dr Schultheis, Dr…
🤙🏻 Excited and proud of presenting the #ABRUPT trial @ASTRO 🙏 to all 1️⃣-fraction believers who followed me in this fool and amazing project @CChissotti @Fefe_Ferrario @Raffa_Lucchini @MariaBelmonte95 @riccardo_ray @valefacc22 @PanizzaDenis
In the CONVERT trial, survival in the BDRT arm was numerically higher. According to the trial statisticians, if approximately 800 patients had been recruited, we would likely have demonstrated the superiority of BDRT! It would be of interest to see the lymphopenia data for LU005
Maybe a silly question, but is it possible the BID RT group was younger, fitter, or had more favorable tumors? I’m really puzzled by the BID subgroups in ADRIATIC and LU005. If the signal is this strong, why didn’t CONVERT or CALGB 30610/RTOG 0538 show the same? Alternatively,…
Friends = colleagues at Lung Cancer Cocktail with Science meeting chaired by @GLoRussoMD_PhD Great to spend time with @JordiRemon @AndrearicFili @RobertoFerrara_ @LuisPaz_Ares @ElinardouHelena Tina Cascone @marinagarassino @PrelajArsela @claudia_proto @GLoRussoMD_PhD
Very informative perspective from @AndrearicFili on the evolution of radiotherapy for stage III NSCLC. Some important studies ongoing but recent negative trials (like PACIFIC-2) give pause. Pros and cons with induction approaches - need to watch for early progression.
United States Trends
- 1. Mike 1,74 Mn posts
- 2. Serrano 233 B posts
- 3. #NetflixFight 68,8 B posts
- 4. Canelo 15,4 B posts
- 5. #netflixcrash 15,1 B posts
- 6. Father Time 10,8 B posts
- 7. Logan 75,7 B posts
- 8. Rosie Perez 14,2 B posts
- 9. Shaq 15,4 B posts
- 10. #buffering 10,6 B posts
- 11. Boxing 283 B posts
- 12. He's 58 21,6 B posts
- 13. ROBBED 99,9 B posts
- 14. My Netflix 80,9 B posts
- 15. Tori Kelly 4.969 posts
- 16. Ramos 69,9 B posts
- 17. Roy Jones 6.954 posts
- 18. Cedric 21,2 B posts
- 19. Gronk 6.471 posts
- 20. Barrios 50,3 B posts
Who to follow
-
Ben Slotman
@bslotman -
Icro Meattini
@Icro_Meattini -
Matthias Guckenberger
@Mat_Guc -
Filippo Alongi
@alongi_filippo -
Pierre Blanchard, MD
@PBlanchardMD -
Dan Trifiletti, MD
@DanTrifMD -
Cliff Robinson
@SBRT_CR -
Carmelo Tuscano🇮🇹🇪🇺
@CTuscanoMD -
Thomas Zilli
@ZilliThomas -
Stefano Arcangeli
@StAr_MCM74 -
Luca Nicosia MD
@NicosiaMd -
Amar Kishan
@AmarUKishan -
Giulio Francolini
@GiulioFrancoli1 -
Corinne Faivre-Finn
@finn_corinne -
Chelsea Miller, MD
@chelseajm28
Something went wrong.
Something went wrong.